^
    3d
    BYON4228.001: First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Byondis B.V. | Recruiting --> Active, not recruiting | N=100 --> 17 | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Oct 2025 --> Feb 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • BYON4228
    4d
    T-cell engaging antibodies for B-cell lymphomas. (PubMed, Semin Hematol)
    This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas. All 4 CD20 × CD3 BsAbs are approved as third-line and beyond therapies: mosunetuzumab for follicular lymphoma (FL), glofitamab for diffuse large B-cell lymphoma (DLBCL), and epcoritamab and odronextamab for both FL and DLBCL (the latter in European Union only)...Multiple studies are currently evaluating these agents in both the relapsed/refractory and frontline settings, either as monotherapy or in combination with other agents. This review summarizes the efficacy and safety of each agent across B-cell lymphoma subtypes, along with their dosing schedules and CRS mitigation strategies.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ordspono (odronextamab) • surovatamig (AZD0486)
    4d
    Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate. (PubMed, Hum Pathol)
    Because both primary (88%) and secondary (95%) skin FLs showed a high incidence of BCL2 expression, most skin FLs may represent one aspect of BCL2+ FL. These findings suggest that BM and duodenum FLs may represent early-phase BCL2+ FL, whereas EN, GI (excluding duodenum), and LN FLs may correspond to more advanced phases.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    4d
    huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    huCART19-IL18
    5d
    Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (clinicaltrials.gov)
    P1/2, N=30, Suspended, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Dec 2026 | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    LDH elevation
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Lymphir (denileukin diftitox-cxdl)
    5d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    5d
    AMC-112: Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    7d
    NCI-2018-01123: Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=17, Completed, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    8d
    Biomarkers Informed by Single-Cell and Spatial Transcriptomics - Biomarkers for Grade 3 Follicular Lymphoma. (PubMed, Mod Pathol)
    In conclusion, AID, CXCR4, CD71, and Ki67 are promising biomarkers for objectively identifying FL grade 3, potentially enhancing the reproducibility of grading and serving as independent prognostic tools. Further clinical validation in uniformly treated FL cohorts is warranted.
    Journal • IO biomarker
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • TFRC • CD40 (CD40 Molecule)
    10d
    A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    |
    MALT1 (MALT1 Paracaspase)
    10d
    EPCORE NHL-2: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (clinicaltrials.gov)
    P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)
    10d
    Aquarius: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P=N/A, N=550, Not yet recruiting, Tempus AI | N=50 --> 550 | Initiation date: Nov 2025 --> Mar 2026
    Enrollment change • Trial initiation date